Tirzepatide is a single peptide co-agonist of GLP-1 and GIP receptors. The dual mechanism provides additive effects on insulin secretion, appetite suppression, and fat utilisation. In clinical trials, it demonstrated superior weight loss to semaglutide.
FDA-approved start: 2.5 mg/week, escalate every 4 weeks to maintenance dose of 5–15 mg/week.
Manufacturer pens: 2–8°C. Research vials: 2–8°C. Do not freeze.
FDA approved as Mounjaro (T2D) and Zepbound (obesity). SURMOUNT trials showed 20%+ body weight reduction at maximum doses.
⚠ For research and educational purposes only. This is not medical advice and does not constitute a recommendation for human use. Consult a licensed healthcare provider. Regulatory status varies by jurisdiction.